Institutional Investors Are Crazy For Integrated Biopharma Inc (NYSE:INB)

December 7, 2017 - By Darrin Black

 Institutional Investors Are Crazy  For Integrated Biopharma Inc (NYSE:INB)

Sentiment for Integrated Biopharma Inc (NYSE:INB)

Integrated Biopharma Inc (NYSE:INB) institutional sentiment increased to 1.33 in 2017 Q2. Its up 0.39, from 0.94 in 2017Q1. The ratio is more positive, as 16 institutional investors increased or opened new equity positions, while 12 sold and decreased their holdings in Integrated Biopharma Inc. The institutional investors in our partner’s database now possess: 2.76 million shares, down from 3.09 million shares in 2017Q1. Also, the number of institutional investors holding Integrated Biopharma Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 8 Increased: 10 New Position: 6.

The stock decreased 0.41% or $0.04 during the last trading session, reaching $9.7. About 73,819 shares traded. Cohen & Steers Global Income Builder, Inc (NYSE:INB) has risen 7.96% since December 7, 2016 and is uptrending. It has underperformed by 8.74% the S&P500.

Cutter & Co Brokerage Inc. holds 0.22% of its portfolio in Cohen & Steers Global Income Builder, Inc for 57,810 shares. Karpus Management Inc. owns 280,866 shares or 0.14% of their US portfolio. Moreover, Girard Partners Ltd. has 0.08% invested in the company for 37,311 shares. The Alabama-based Kistler has invested 0.03% in the stock. Avalon Advisors Llc, a Texas-based fund reported 50,435 shares.#img1#

Another recent and important Cohen & Steers Global Income Builder, Inc (NYSE:INB) news was published by Nasdaq.com which published an article titled: “Cohen & Steers Global Income Builder, Inc. (INB) Ex-Dividend Date Scheduled …” on September 19, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: